Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Carcinoma, Medullary 3Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms by Site 2Neoplasms 2Lung Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Colonic Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Sarcoma 1Myofibromatosis 1

Interventions

selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Myofibromatosis × selpercatinib × Clear all
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡